Effects of Exenatide on Hypothalamic Obesity
Primary Purpose
Hypothalamic Obesity
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Exenatide
Sponsored by

About this trial
This is an interventional treatment trial for Hypothalamic Obesity focused on measuring Hypothalamic Obesity, Exenatide, Byetta, Craniopharyngioma
Eligibility Criteria
Inclusion Criteria:
- >/=6 months post surgical or radiation or chemotherapy treatment for 1° craniopharyngiomas or other suprasellar tumors
- 10-21 years old
- Age-and sex-adjusted BMI >/=95%
- Parent sign consent and patient sign assent
Exclusion Criteria:
- < 6 months post surgical or radiation or chemotherapy treatment for 1° craniopharyngiomas or other suprasellar tumors
- Pregnant or breastfeeding, or those women who plan to get pregnant
- Renal impairment
- Gastroparesis
- Pancreatitis
- Diabetes
- <1 month post initiation of Metformin treatment
- Prescription or over-the-counter weight loss medications within 3 months of screening
- Are actively participating in, or have participated in a formal weight loss program within the last 3 months
- Have had bariatric surgery
Sites / Locations
- Children's Hospital of Orange County
- Children's Hospitals & Clincis of Minnesota
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Exenatide
Arm Description
5mcg of exenatide will be given twice a day for 4 weeks and increased to 10 mcg twice a day for 20 weeks.
Outcomes
Primary Outcome Measures
BMI Change
BMI was collected at baseline and 24 weeks
Waist to Height Ratio (WHtR)
Waist circumference was measured at the natural waist level (midway between the lowest rib margin and the iliac crest) at baseline and 24 weeks
Secondary Outcome Measures
Childhood Eating Behavior Questionnaire (CEBQ)
The Child Eating Behaviour Questionnaire (CEBQ) was designed as parent-report measure comprised of 35 items, each rated on a five-point likert scale that ranges from never to always. We utilized the CEBQ as a self-report measure during this study; it has not been validated for such use. For the purposes of this study, we looked at the Satiety Responsiveness Subscale Scores (5 questions; total scores could range from 5-25 with lower scores denoting a lower level of satiety). The results reported show the change between baseline and week 24 scores.
Calorie Intake Based on 3-day Diet Records
Dietary data were collected via 3-day diet records (Crawford et al. 1994) twice during the study, at baseline and week 24. Three-day diet records were collected on consecutive days including one weekend day. A registered dietitian (RD) instructed subjects on dietary data collection at baseline appointment. Depending on the age and capacity of the subject, the patient, parent or a collaboration of both recorded dietary intake. A RD entered dietary data into Nutritionist Pro software (First DataBank, SanBruno, CA) and the mean difference was analyzed.
Full Information
NCT ID
NCT01061775
First Posted
February 2, 2010
Last Updated
September 24, 2019
Sponsor
Children's Hospitals and Clinics of Minnesota
Collaborators
Amylin Pharmaceuticals, LLC.
1. Study Identification
Unique Protocol Identification Number
NCT01061775
Brief Title
Effects of Exenatide on Hypothalamic Obesity
Official Title
Effects of Exenatide on Hypothalamic Obesity
Study Type
Interventional
2. Study Status
Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
July 2013 (Actual)
Study Completion Date
March 15, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Children's Hospitals and Clinics of Minnesota
Collaborators
Amylin Pharmaceuticals, LLC.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The primary aim of this study is to evaluate the effect of Exenatide on weight status (change in body mass index) of children treated for craniopharyngioma that have developed hypothalamic obesity at Children's Hospitals and Clinics of Minnesota. We hypothesize that Exenatide given to hypothalamic obese children for 6 months will reduce their body mass index significantly from baseline.
Detailed Description
Hypothalamic obesity is when individuals suffer from acute weight gain after brain tumor treatment, involving secondary damage to the ventromedial nucleus of the hypothalamus, which may lead to obesity. The weight gain is uncontrolled and not receptive to diet and exercise interventions. The rate of long-term obesity in children diagnosed with craniopharyngioma can be as high as 50%. Exenatide, a drug indicated for diabetes, is an incretin mimicking agent that mimics the enhancement of glucose-dependent insulin secretion and several other antihyperglycemic actions of incretins has resulted in weight loss when given to diabetics. Exenatide shows potential to benefit patients suffering from hypothalamic obesity by slowing gastric emptying and therefore reducing food intake. Also increasing the glucagon-like peptide 1 (GLP-1) circulation, decreased due to obesity, at the already compromised GLP-1 receptor site of the hypothalamus could potentially help with regulation of appetite.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypothalamic Obesity
Keywords
Hypothalamic Obesity, Exenatide, Byetta, Craniopharyngioma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
19 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Exenatide
Arm Type
Experimental
Arm Description
5mcg of exenatide will be given twice a day for 4 weeks and increased to 10 mcg twice a day for 20 weeks.
Intervention Type
Drug
Intervention Name(s)
Exenatide
Other Intervention Name(s)
Byetta
Intervention Description
5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.
Primary Outcome Measure Information:
Title
BMI Change
Description
BMI was collected at baseline and 24 weeks
Time Frame
24 weeks
Title
Waist to Height Ratio (WHtR)
Description
Waist circumference was measured at the natural waist level (midway between the lowest rib margin and the iliac crest) at baseline and 24 weeks
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Childhood Eating Behavior Questionnaire (CEBQ)
Description
The Child Eating Behaviour Questionnaire (CEBQ) was designed as parent-report measure comprised of 35 items, each rated on a five-point likert scale that ranges from never to always. We utilized the CEBQ as a self-report measure during this study; it has not been validated for such use. For the purposes of this study, we looked at the Satiety Responsiveness Subscale Scores (5 questions; total scores could range from 5-25 with lower scores denoting a lower level of satiety). The results reported show the change between baseline and week 24 scores.
Time Frame
24 weeks
Title
Calorie Intake Based on 3-day Diet Records
Description
Dietary data were collected via 3-day diet records (Crawford et al. 1994) twice during the study, at baseline and week 24. Three-day diet records were collected on consecutive days including one weekend day. A registered dietitian (RD) instructed subjects on dietary data collection at baseline appointment. Depending on the age and capacity of the subject, the patient, parent or a collaboration of both recorded dietary intake. A RD entered dietary data into Nutritionist Pro software (First DataBank, SanBruno, CA) and the mean difference was analyzed.
Time Frame
24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
>/=6 months post surgical or radiation or chemotherapy treatment for 1° craniopharyngiomas or other suprasellar tumors
10-21 years old
Age-and sex-adjusted BMI >/=95%
Parent sign consent and patient sign assent
Exclusion Criteria:
< 6 months post surgical or radiation or chemotherapy treatment for 1° craniopharyngiomas or other suprasellar tumors
Pregnant or breastfeeding, or those women who plan to get pregnant
Renal impairment
Gastroparesis
Pancreatitis
Diabetes
<1 month post initiation of Metformin treatment
Prescription or over-the-counter weight loss medications within 3 months of screening
Are actively participating in, or have participated in a formal weight loss program within the last 3 months
Have had bariatric surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
M. Jennifer Abuzzahab, MD
Organizational Affiliation
Children's Hospitals & Clinics of Minnesota
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Hospital of Orange County
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Children's Hospitals & Clincis of Minnesota
City
Saint Paul
State/Province
Minnesota
ZIP/Postal Code
55102
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
We do not plan to share individual participant data.
Links:
URL
http://www.childrensmn.org/
Description
Hospital website
Learn more about this trial
Effects of Exenatide on Hypothalamic Obesity
We'll reach out to this number within 24 hrs